Toward Equitable Risk Classification for All Patients with T-ALL.

IF 11.5 Q1 HEMATOLOGY

Blood Cancer Discovery Pub Date : 2025-09-03 DOI:10.1158/2643-3230.BCD-25-0221

Adam J de Smith

引用次数: 0

Abstract

In this issue of Blood Cancer Discovery, Newman and colleagues investigated the impact of genetic ancestry on molecular subtypes, genomic alterations, and survival outcomes in a diverse cohort of patients with T-cell acute lymphoblastic leukemia. They demonstrated that the prognostic utility of genomic alterations varied by ancestry, in particular, with NOTCH1 mutations having no prognostic utility in patients of predominantly African ancestry, and their findings highlight the importance of considering genetic ancestry in the risk stratification of patients with T-ALL. See related article by Newman et al., p. 412.

查看原文本刊更多论文

对所有T-ALL患者进行公平的风险分类。

在这一期的《血癌发现》中，Newman和他的同事研究了遗传祖先对分子亚型、基因组改变和t细胞急性淋巴细胞白血病患者生存结果的影响。他们证明了基因组改变的预后效用因祖先而异，特别是NOTCH1突变在主要是非洲血统的患者中没有预后效用，他们的发现强调了在T-ALL患者的风险分层中考虑遗传祖先的重要性。参见纽曼等人的相关文章，第XX页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.